Fig. 2From: Selenium nanoparticles (SeNPs) have potent antitumor activity against prostate cancer cells through the upregulation of miR-16SeNP treatment lead to cell cycle arrest in LNCaP and LNCaP-A cells. a, b Cell cycle analysis in a LNCaP and b LNCaP-A after SeNP treatment. c, d Expression of p21 (CDKN1A, c) in c LNCaP and d LNCaP-A after SeNP treatment. e, f Expression of cyclin D1 in a LNCaP and b LNCaP-A after SeNP treatment. SeNP dose: 50 μgBack to article page